Osteologix, Inc. (OTC BB: OLGX), a specialty biopharmaceutical company, has dedicated their efforts to improving the health of those afflicted with musculoskeletal diseases through the development of innovative therapies. NB S101, the company’s lead investigational product candidate, is an innovative pharmaceutical agent designed to treat and prevent osteoporosis. Their mission is to partner with the healthcare community to apply new scientific information to the development of beneficial products. For more information please visit www.osteologix.com.
- 17 years ago
QualityStocks
Osteologix, Inc. (OTC BB: OLGX)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
Safe Pro Group delivers AI, drone-based services, and ballistic protective gear, to customers in the…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…